OK100

OK100 is an investigational **equine allogeneic stem cell therapy** developed by Celavet for veterinary regenerative medicine applications, particularly tendon injury in horses. Published descriptions identify it as a fetal tissue-derived, embryonic-like or pluripotent equine stem cell product intended for intralesional administration into injured tendon, with the therapeutic rationale of promoting tissue regeneration, improving tendon fiber organization, and modulating the local repair environment rather than acting through a single defined receptor target. Available public information links OK100 primarily to development for **equine tendinitis** and related tendon or ligament injuries; however, its precise molecular mechanism, final commercial formulation, and regulatory outcome are not well characterized in accessible sources.

Other names

undifferentiated allogeneic pluripotent equine stem cellsfetal-derived embryonic-like stem cellsequine fetal tissue-derived embryonic-like stem cells